Skip to main content
Oxurion NV logo

Oxurion NV — Investor Relations & Filings

Ticker · OXUR ISIN · BE0974487192 LEI · 549300VWY8KVDFKLDM59 BR Professional, scientific and technical activities
Open in API
Filings indexed 1,031 across all filing types
Latest filing 2017-09-29 Proxy Solicitation & In…
Country BE Belgium
Listing BR OXUR

About Oxurion NV

https://oxurion.com/

Oxurion NV is a company focused on acquiring majority stakes in European pharmaceutical subcontractors. Its strategy is to build an integrated group of contract service providers to support healthcare stakeholders. A key asset in its portfolio is a majority stake in Axiodis CRO, a contract research organization specializing in biometrics. This investment-based business model represents a strategic pivot from the company's former focus on the internal research and development of therapies for retinal diseases such as Geographic Atrophy (GA) and Age-related Macular Degeneration (AMD).

Recent filings

Filing Released Lang Actions
3-Shareholders’ rights pursuant to Art. 533ter and 540 BCC EGM 2017 (Dutch).pdf
Proxy Solicitation & Information Statement Classification · 98% confidence The document text details the rights of shareholders regarding placing items on the agenda and submitting written questions for an upcoming 'buitengewone algemene vergadering' (Extraordinary General Meeting) scheduled for October 30, 2017. It specifies deadlines for submitting proposals (October 8, 2017) and written questions (October 24, 2017), and the record date (October 16, 2017). This content is directly related to the procedures and information provided to shareholders in preparation for a general meeting, which aligns perfectly with the definition of Proxy Solicitation & Information Statement (PSI). It is not the AGM presentation itself (AGM-R), nor is it a full annual report (10-K) or an earnings release (ER).
2017-09-29 Dutch
2-THR Proxy form for the extraordinary shareholders meeting 2017 (D&EN).pdf
AGM Information Classification · 98% confidence The document text is in Dutch and explicitly refers to a 'bijzondere algemene vergadering' (Extraordinary General Meeting) scheduled for October 30, 2017. It contains a 'VOLMACHT' (Proxy Form) for shareholders to appoint a representative for this meeting and details the 'Agenda van de bijzondere algemene vergadering' (Agenda of the Extraordinary General Meeting). The agenda items discuss warrant plans and capital increases, which are typical topics for shareholder meetings. Since the document is the proxy form and agenda materials for a general meeting, it strongly aligns with the definition of AGM Information (AGM-R). It is not a full Annual Report (10-K), an Earnings Release (ER), or a simple announcement of a report (RPA/RNS), but rather the core material related to the meeting itself.
2017-09-29 Dutch
1-THR Convening Notice EGM 2017 (Dutch).pdf
AGM Information Classification · 98% confidence The document is titled "OPROEPING TOT BUITENGEWONE ALGEMENE VERGADERING VAN AANDEELHOUDERS" (Call for Extraordinary General Meeting of Shareholders) and details the agenda, including proposals for a new warrant plan and a capital increase via a private placement to Novartis Pharma AG. The text explicitly calls shareholders to attend a meeting on a specific date (October 30, 2017) to vote on resolutions. This content is characteristic of materials distributed to shareholders in preparation for a general meeting, which falls under the scope of AGM materials or proxy solicitation information. Since it is a formal call to an Extraordinary General Meeting (EGM) detailing the agenda and resolutions, the most appropriate classification is AGM-R (AGM Information), as it directly relates to the meeting itself, rather than just the proxy solicitation materials (PSI) or a general regulatory filing (RNS). The document length is substantial (over 26k characters), indicating it is the full notice/agenda, not just a brief announcement.
2017-09-29 Dutch
ThromboGenics Regains Global Rights to JETREA (ocriplasmin)
M&A Activity Classification · 99% confidence The document is a press release dated September 18, 2017, announcing that ThromboGenics NV is regaining global rights to the drug JETREA® from Alcon/Novartis, including details of the financial consideration (€53.7 million cash plus a €10 million equity investment). This announcement details a significant corporate transaction involving asset rights and financing/capital structure implications. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a quarterly report (IR). It specifically details a transaction that impacts the company's structure and financing. The closest fit among the provided codes is 'Capital/Financing Update' (CAP) due to the explicit mention of receiving significant cash and an equity investment, which alters the capital structure, or 'Regulatory Filings' (RNS) as a general announcement. However, since the core event is a major transaction involving asset rights and associated funding, 'CAP' is more specific than the general 'RNS' fallback. It is not a merger/takeover (TAR), but a specific asset/rights transaction with a financing component. Given the focus on the financial terms of the agreement and the resulting cash position, CAP is the most appropriate classification.
2017-09-18 English
THR_HY BU 70917_EN.pdf
Interim / Quarterly Report Classification · 95% confidence The document is a 'Business Update' for the first half of 2017 (H1 2017) issued by ThromboGenics. It contains substantive financial data, including revenue figures (€2.7 million) and cash position (€65.1 million), as well as detailed operational updates on clinical trials and pipeline development. Because it covers a period shorter than a full fiscal year and provides comprehensive financial and operational analysis, it is classified as an Interim/Quarterly Report. H1 2017
2017-09-07 English
THR_HY BU 070917_NL.pdf
Interim / Quarterly Report Classification · 95% confidence The document is a 'Business Update' for the first half of 2017 (H1 2017) for ThromboGenics. It provides a detailed review of the company's clinical pipeline, research progress, and financial highlights (cash position, revenue). It contains substantive financial and operational analysis rather than just an announcement of a report. Therefore, it qualifies as an Interim/Quarterly Report. H1 2017
2017-09-07 Dutch

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.